Melanoma chemoprevention

Journal of the American Academy of Dermatology

Volumn 55, Issue 5, 2006, Pages 849-861

  Francis, Shayla O ^b   Mahlberg, Matthew J ^c   Johnson, Kathryn R ^b   Ming, Michael E ^c   Dellavalle, Robert P ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANTILIPEMIC AGENT; BETA CAROTENE; CYCLOOXYGENASE 2 INHIBITOR; DEOXYRIBONUCLEASE (PYRIMIDINE DIMER); EFLORNITHINE; EPIGALLOCATECHIN GALLATE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FLAVONOID; GEMFIBROZIL; GENISTEIN; GINSENG EXTRACT; GREEN TEA EXTRACT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMIQUIMOD; IMMUNOMODULATING AGENT; LYCOPENE; MEVINOLIN; NONSTEROID ANTIINFLAMMATORY AGENT; PERILLYL ALCOHOL; PROANTHOCYANIDIN DERIVATIVE; RESVERATROL; RETINOID DERIVATIVE; SELENIUM; SILYMARIN; SUNSCREEN; UNINDEXED DRUG; VACCINE; VITAMIN D;

ALOPECIA; ANOREXIA; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTHRALGIA; BLEEDING; BLISTER; BLURRED VISION; BONE DISEASE; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER PREVENTION; CANCER RISK; CENTRAL NERVOUS SYSTEM DISEASE; CHEILITIS; CLINICAL TRIAL; CONSTIPATION; DERMATITIS; DIARRHEA; DIZZINESS; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG MECHANISM; ERYTHEMA; EYE DISEASE; FATIGUE; FLU LIKE SYNDROME; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HAIR LOSS; HEART DISEASE; HEART PALPITATION; HUMAN; HYPERCALCEMIA; HYPERPLASIA; IMMUNOMODULATION; INFECTION; INSOMNIA; IRRITABILITY; KIDNEY DISEASE; LIPID BLOOD LEVEL; LIVER DISEASE; LIVER NECROSIS; LIVER TOXICITY; MELANOCYTIC NEVUS; MELANOMA; MENSTRUAL IRREGULARITY; MENTAL STRESS; META ANALYSIS; METABOLIC ACIDOSIS; MUSCLE DISEASE; MUSCLE WEAKNESS; MYCOSIS; NAUSEA; NEPHROLITHIASIS; NEPHROTOXICITY; NONHUMAN; OTOTOXICITY; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SEIZURE; SIDE EFFECT; SKIN CANCER; SKIN DISCOLORATION; SKIN IRRITATION; SUN EXPOSURE; SUNBURN; SYSTEMATIC REVIEW; TERATOGENICITY; THIRST; THROMBOEMBOLISM; VOMITING; XEROSIS;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTILIPEMIC AGENTS; CHEMOPREVENTION; HUMANS; IMMUNOLOGIC FACTORS; MELANOMA; NUTRITION THERAPY; SKIN NEOPLASMS; SUNSCREENING AGENTS; VACCINES;

EID: 33749684978     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2006.04.014     Document Type: Review

References (189)

1. American Cancer Society. Cancer facts and figures 2005 (2005), American Cancer Society, Atlanta
2. Gandini S., Sera F., Cattaruzza M.S., Pasquini P., Abeni D., Boyle P., et al. Meta-analysis of risk factors for cutaneous melanoma, I: common and atypical nevi. Eur J Cancer 41 (2005) 28-44
3. Gandini S., Sera F., Cattaruzza M.S., Pasquini P., Zanetti R., Masini C., et al. Meta-analysis of risk factors for cutaneous melanoma, III: family history, actinic damage and phenotypic factors. Eur J Cancer 41 (2005) 2040-2059
4. Gandini S., Sera F., Cattaruzza M.S., Pasquini P., Picconi O., Boyle P., et al. Meta-analysis of risk factors for cutaneous melanoma, II: sun exposure. Eur J Cancer 41 (2005) 45-60
5. Gilchrest B.A., Eller M.S., Geller A.C., and Yaar M. The pathogenesis of melanoma induced by ultraviolet radiation. N Engl J Med 340 (1999) 1341-1348
6. Zelnak A.B., and O'Regan R.M. Chemoprevention of breast cancer. Curr Probl Cancer 28 (2004) 201-217
7. Klein E.A., and Thompson I.M. Update on chemoprevention of prostate cancer. Curr Opin Urol 14 (2004) 143-149
8. Raju R., and Cruz-Correa M. Chemoprevention of colorectal cancer. Dis Colon Rectum 49 (2006) 113-124
9. Del Rosso J.Q. New and emerging topical approaches for actinic keratoses. Cutis 72 (2003) 273-6, 279
10. Dellavalle R.P., Nicholas M.K., and Schilling L.M. Melanoma chemoprevention: a role for statins or fibrates?. Am J Ther 10 (2003) 203-210
11. Hong W.K., Spitz M.R., and Lippman S.M. Cancer chemoprevention in the 21st century: genetics, risk modeling, and molecular targets. J Clin Oncol 18 Suppl (2000) 9S-18S
12. Demierre M.F., and Sondak V.K. Cutaneous melanoma: pathogenesis and rationale for chemoprevention. Crit Rev Oncol Hematol 53 (2005) 225-239
13. Moloney F.J., Collins S., and Murphy G.M. Sunscreens: safety, efficacy and appropriate use. Am J Clin Dermatol 3 (2002) 185-191
14. Rodenas J.M., Delgado-Rodriguez M., Herranz M.T., Tercedor J., and Serrano S. Sun exposure, pigmentary traits, and risk of cutaneous malignant melanoma: a case-control study in a Mediterranean population. Cancer Causes Control 7 (1996) 275-283
15. Espinosa A.J., Sanchez H.J., Bravo Fernandez P., Gonzalez-Baron M., Zamora A.P., Espinosa A.E., et al. Cutaneous malignant melanoma and sun exposure in Spain. Melanoma Res 9 (1999) 199-205
16. Bakos L., Wagner M., Bakos R.M., Leite C.S., Sperhacke C.L., Dzekaniak K.S., et al. Sunburn, sunscreens, and phenotypes: some risk factors for cutaneous melanoma in southern Brazil. Int J Dermatol 41 (2002) 557-562
17. Naldi L., Gallus S., Imberti G.L., Cainelli T., Negri E., and La Vecchia C. Sunscreens and cutaneous malignant melanoma: an Italian case-control study. Int J Cancer 86 (2000) 879-882
18. Huncharek M., and Kupelnick B. Use of topical sunscreens and the risk of malignant melanoma: a meta-analysis of 9067 patients from 11 case-control studies. Am J Public Health 92 (2002) 1173-1177
19. Dennis L.K., Beane Freeman L.E., and VanBeek M.J. Sunscreen use and the risk for melanoma: a quantitative review. Ann Intern Med 139 (2003) 966-978
20. Westerdahl J., Olsson H., Masback A., Ingvar C., and Jonsson N. Is the use of sunscreens a risk factor for malignant melanoma?. Melanoma Res 5 (1995) 59-65
21. Westerdahl J., Ingvar C., Masback A., and Olsson H. Sunscreen use and malignant melanoma. Int J Cancer 87 (2000) 145-150
22. Autier P., Dore J.F., Schifflers E., Cesarini J.P., Bollaerts A., Koelmel K.F., et al. Melanoma and use of sunscreens: an EORTC case-control study in Germany, Belgium and France, the EORTC melanoma cooperative group. Int J Cancer 61 (1995) 749-755
23. Bastuji-Garin S., and Diepgen T.L. Cutaneous malignant melanoma, sun exposure, and sunscreen use: epidemiological evidence. Br J Dermatol 146 Suppl (2002) 24-30
24. Rigel D.S. The effect of sunscreen on melanoma risk. Dermatol Clin 20 (2002) 601-606
25. Weinstock M.A. Do sunscreens increase or decrease melanoma risk: an epidemiologic evaluation. J Investig Dermatol Symp Proc 4 (1999) 97-100
26. Wang S.O., Setlow R., Berwick M., Polsky D., Marghoob A.A., Kopf A.W., et al. Ultraviolet A and melanoma: a review. J Am Acad Dermatol 44 (2001) 837-846
27. Nghiem D.X., Kazimi N., Clydesdale G., Ananthaswamy H.N., Kripke M.L., and Ullrich S.E. Ultraviolet A radiation suppresses an established immune response: implications for sunscreen design. J Invest Dermatol 117 (2001) 1193-1199
28. Al Mahroos M., Yaar M., Phillips T.J., Bhawan J., and Gilchrest B.A. Effect of sunscreen application on UV-induced thymine dimers. Arch Dermatol 138 (2002) 1480-1485
29. Bauer J., Buttner P., Wiecker T.S., Luther H., and Garbe C. Effect of sunscreen and clothing on the number of melanocytic nevi in 1,812 German children attending day care. Am J Epidemiol 161 (2005) 620-627
30. Lee T.K., Rivers J.K., and Gallagher R.P. Site-specific protective effect of broad-spectrum sunscreen on nevus development among white schoolchildren in a randomized trial. J Am Acad Dermatol 52 (2005) 786-792
31. English D.R., Milne E., Jacoby P., Giles-Corti B., Cross D., and Johnston R. The effect of a school-based sun protection intervention on the development of melanocytic nevi in children: 6-year follow-up. Cancer Epidemiol Biomarkers Prev 14 (2005) 977-980
32. Holly E.A., Kelly J.W., Shpall S.N., and Chiu S.H. Number of melanocytic nevi as a major risk factor for malignant melanoma. J Am Acad Dermatol 17 (1987) 459-468
33. Nash J.F. Human safety and efficacy of ultraviolet filters and sunscreen products. Dermatol Clin 24 (2006) 35-51
34. Versluis A.J., van Geel P.J., Oppelaar H., van Berkel T.J., and Bijsterbosch M.K. Receptor-mediated uptake of low-density lipoprotein by B16 melanoma cells in vitro and in vivo in mice. Br J Cancer 74 (1996) 525-532
35. Buchwald H. Cholesterol inhibition, cancer, and chemotherapy. Lancet 339 (1992) 1154-1156
36. Lenz M., Miehe W.P., Vahrenwald F., Bruchelt G., Schweizer P., and Girgert R. Cholesterol based antineoplastic strategies. Anticancer Res 17 (1997) 1143-1146
37. Demierre M.F., Higgins P.D., Gruber S.B., Hawk E., and Lippman S.M. Statins and cancer prevention. Nat Rev Cancer 5 (2005) 930-942
38. Collisson E.A., Carranza D.C., Chen I.Y., and Kolodney M.S. Isoprenylation is necessary for the full invasive potential of RhoA overexpression in human melanoma cells. J Invest Dermatol 119 (2002) 1172-1176
39. Jani J.P., Specht S., Stemmler N., Blanock K., Singh S.V., Gupta V., et al. Metastasis of B16F10 mouse melanoma inhibited by lovastatin, an inhibitor of cholesterol biosynthesis. Invasion Metastasis 13 (1993) 314-324
40. Chan K.K., Oza A.M., and Siu L.L. The statins as anticancer agents. Clin Cancer Res 9 (2003) 10-19
41. Graaf M.R., Beiderbeck A.B., Egberts A.C., Richel D.J., and Guchelaar H.J. The risk of cancer in users of statins. J Clin Oncol 22 (2004) 2388-2394
42. Downs J.R., Clearfield M., Weis S., Whitney E., Shapiro D.R., Beere P.A., et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS, Air Force/Texas coronary atherosclerosis prevention study. JAMA 279 (1998) 1615-1622
43. Kaye J.A., and Jick H. Statin use and cancer risk in the general practice research database. Br J Cancer 90 (2004) 635-637
44. Dellavalle R., Drake A., Graber M., Heilig L., Hester E., Johnson K., et al. Statins and fibrates for preventing melanoma. Cochrane Database Syst Rev 4 (2005) CD003697
45. Dale K.M., Coleman C.I., Henyan N.N., Kluger J., and White C.M. Statins and cancer risk: a meta-analysis. JAMA 295 (2006) 74-80
46. Escher P., and Wahli W. Peroxisome proliferator-activated receptors: insight into multiple cellular functions. Mutat Res 448 (2000) 121-138
47. Mossner R., Schulz U., Kruger U., Middel P., Schinner S., Fuzesi L., et al. Agonists of peroxisome proliferator-activated receptor gamma inhibit cell growth in malignant melanoma. J Invest Dermatol 119 (2002) 576-582
48. Placha W., Gil D., Dembinska-Kiec A., and Laidler P. The effect of PPARgamma ligands on the proliferation and apoptosis of human melanoma cells. Melanoma Res 13 (2003) 447-456
49. Grabacka M., Placha W., Plonka P.M., Pajak S., Urbanska K., Laidler P., et al. Inhibition of melanoma metastases by fenofibrate. Arch Dermatol Res 296 (2004) 54-58
50. Sleijfer S., van der Gaast A., Planting A.S.T., Stoter G., and Verwij J. The potential of statins as part of anti-cancer treatment. Eur J Cancer 41 (2005) 516-522
51. Fischer S.M., Lo H.H., Gordon G.B., Seibert K., Kelloff G., Lubet R.A., et al. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, and indomethacin against ultraviolet light-induced skin carcinogenesis. Mol Carcinog 25 (1999) 231-240
52. Pentland A.P., Schoggins J.W., Scott G.A., Khan K.N., and Han R. Reduction of UV-induced skin tumors in hairless mice by selective COX-2 inhibition. Carcinogenesis 20 (1999) 1939-1944
53. Pelzmann M., Thurnher D., Gedlicka C., Martinek H., and Knerer B. Nimesulide and indomethacin induce apoptosis in head and neck cancer cells. J Oral Pathol Med 33 (2004) 607-613
54. Chan A.T., Giovannucci E.L., Schernhammer E.S., Colditz G.A., Hunter D.J., Willett W.C., et al. A prospective study of aspirin use and the risk for colorectal adenoma. Ann Intern Med 140 (2004) 157-166
55. Shen J., Wanibuchi H., Salim E.I., Wei M., Yamachika T., and Fukushima S. Inhibition of azoxymethane-induced colon carcinogenesis in rats due to JTE-522, a selective cyclooxygenase-2 inhibitor. Asian Pac J Cancer Prev 5 (2004) 253-258
56. Terry M.B., Gammon M.D., Zhang F.F., Tawfik H., Teitelbaum S.L., Britton J., et al. Association of frequency and duration of aspirin use and hormone receptor status with breast cancer risk. Obstet Gynecol Surv 59 (2004) 771-773
57. Mazhar D., Ang R., and Waxman J. COX inhibitors and breast cancer. Br J Cancer 94 (2006) 346-350
58. Denkert C., Kobel M., Berger S., Siegert A., Leclere A., Trefzer U., et al. Expression of cyclooxygenase 2 in human malignant melanoma. Cancer Res 61 (2001) 303-308
59. Harris R.E., Beebe-Donk J., Doss H., and Burr Doss D. Aspirin, ibuprofen, and other non-steroidal anti-inflammatory drugs in cancer prevention: a critical review of non-selective COX-2 blockade. Oncol Rep 13 (2005) 559-583
60. Harris R.E., Beebe-Donk J., and Namboodiri K.K. Inverse association of non-steroidal anti-inflammatory drugs and malignant melanoma among women. Oncol Rep 8 (2001) 655-657
61. Ramirez C.C., Ma F., Federman D.G., and Kirsner R.S. Use of cyclooxygenase inhibitors and risk of melanoma in high-risk patients. Dermatol Surg 31 (2001) 748-752
62. Vogt T., McClelland M., Jung B., Popova S., Bogenrieder T., Becker B., et al. Progression and NSAID-induced apoptosis in malignant melanomas are independent of cyclooxygenase II. Melanoma Res 11 (2001) 587-599
63. Cahlin C., Gelin J., Delbro D., Lonnroth C., Doi C., and Lundholm K. Effect of cyclooxygenase and nitric oxide synthase inhibitors on tumor growth in mouse tumor models with and without cancer cachexia related to prostanoids. Cancer Res 60 (2000) 1742-1749
64. Buckman S.Y., Gresham A., Hale P., Hruza G., Anast J., Masferrer J., et al. COX-2 expression is induced by UVB exposure in human skin: implications for the development of skin cancer. Carcinogenesis 19 (1998) 723-729
65. Orengo I.F., Gerguis J., Phillips R., Guevara A., Lewis A.T., and Black H.S. Celecoxib, a cyclooxygenase 2 inhibitor as a potential chemopreventive to UV-induced skin cancer: a study in the hairless mouse model. Arch Dermatol 138 (2002) 751-755
66. Wilgus T.A., Koki A.T., Zweifel B.S., Kusewitt D.F., Rubal P.A., and Oberyszyn T.M. Inhibition of cutaneous ultraviolet light B-mediated inflammation and tumor formation with topical celecoxib treatment. Mol Carcinog 38 (2003) 49-58
67. Fischer S.M., Conti C.J., Viner J., Aldaz C.M., and Lubet R.A. Celecoxib and difluoromethylornithine in combination have strong therapeutic activity against UV-induced skin tumors in mice. Carcinogenesis 24 (2003) 945-952
68. Wilgus T.A., Koki A.T., Zweifel B.S., Rubal P.A., and Oberyszyn T.M. Chemotherapeutic efficacy of topical celecoxib in a murine model of ultraviolet light B-induced skin cancer. Mol Carcinog 38 (2003) 33-39
69. Wilgus T.A., Breza Jr. T.S., Tober K.L., and Oberyszyn T.M. Treatment with 5-fluorouracil and celecoxib displays synergistic regression of ultraviolet light B-induced skin tumors. J Invest Dermatol 122 (2004) 1488-1494
70. Bresalier R.S., Sander R.S., Quan H., Bolognese J.A., Oxenius B., Horgan K., et al. Adenomatous polyp prevention or Vioxx (APPROVe) trial investigators: cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352 (2005) 1092-1102
71. Hsu S. Green tea and the skin. J Am Acad Dermatol 52 (2005) 1049-1059
72. Nihal M., Ahmad N., Mukhtar H., and Wood G.S. Anti-proliferative and proapoptotic effects of epigallocatechin-3-gallate on human melanoma: possible implications for the chemoprevention of melanoma. Int J Cancer 114 (2005) 513-521
73. Tosetti F., Ferrari N., De Flora S., and Albini A. Angioprevention: angiogenesis is a common and key target for cancer chemopreventive agents. FASEB J 16 (2002) 214
74. Einspahr J.G., Stratton S.P., Bowden G.T., and Alberts D.S. Chemoprevention of human skin cancer. Crit Rev Oncol Hematol 41 (2002) 269-285
75. Wang Z.Y., Khan W.A., Bickers D.R., and Mukhtar H. Protection against polycyclic aromatic hydrocarbon-induced skin tumor initiation in mice by green tea polyphenols. Carcinogenesis 10 (1989) 411-415
76. Wang Z.Y., Huang M.T., Lou Y.R., Xie J.G., Reuhl K.R., Newmark H.L., et al. Inhibitory effects of black tea, green tea, decaffeinated black tea, and decaffeinated green tea on ultraviolet B light-induced skin carcinogenesis in 7,12-dimethylbenz[a]anthracene-initiated SKH-1 mice. Cancer Res 54 (1994) 3428-3435
77. Yang C.S., and Wang Z.Y. Tea and cancer. J Natl Cancer Inst 85 (1993) 1038-1049
78. Huang M.T., Xie J.G., Wang Z.Y., Ho C.T., Lou Y.R., Wang C.X., et al. Effects of tea, decaffeinated tea, and caffeine on UVB light-induced complete carcinogenesis in SKH-1 mice: demonstration of caffeine as a biologically important constituent of tea. Cancer Res 57 (1997) 2623-2629
79. Wang Z.Y., Huang M.T., Ho C.T., Chang R., Ma W., Ferraro T., et al. Inhibitory effect of green tea on the growth of established skin papillomas in mice. Cancer Res 52 (1992) 6657-6665
80. Elmets C.A., Singh D., Tubesing K., Matsui M., Katiyar S., and Mukhtar H. Cutaneous photoprotection from ultraviolet injury by green tea polyphenols. J Am Acad Dermatol 44 (2001) 425-432
81. Zhao J.F., Zhang Y.J., Jin X.H., Athar M., Santella R.M., Bickers D.R., et al. Green tea protects against psoralen plus ultraviolet A-induced photochemical damage to skin. J Invest Dermatol 113 (1999) 1070-1075
82. Zhang G., Miura Y., and Yagasaki K. Induction of apoptosis and cell cycle arrest in cancer cells by in vivo metabolites of teas. Nutr Cancer 38 (2000) 265-273
83. Suzuki Y., and Isemura M. Inhibitory effect of epigallocatechin gallate on adhesion of murine melanoma cells to laminin. Cancer Lett 173 (2001) 15-20
84. Taniguchi S., Fujiki H., Kobayashi H., Go H., Miyado K., Sadano H., et al. Effect of (-)-epigallocatechin gallate, the main constituent of green tea, on lung metastasis with mouse B16 melanoma cell lines. Cancer Lett 65 (1992) 51-54
85. Nakachi K., Matsuyama S., Miyake S., Suganuma M., and Imai K. Preventive effects of drinking green tea on cancer and cardiovascular disease: epidemiological evidence for multiple targeting prevention. Biofactors 13 (2000) 49
86. Fujiki H. Green tea: health benefits as cancer preventive for humans. Chem Rec 5 (2005) 119-132
87. Katiyar S.K. Skin photoprotection by green tea: antioxidant and immunomodulatory effects. Curr Drug Targets Immune Endocr Metab Disord 3 (2003) 234-242
88. Zheng W., Doyle T.J., Kushi L.H., Sellers T.A., Hong C.P., and Folsom A.R. Tea consumption and cancer incidence in a prospective cohort study of postmenopausal women. Am J Epidemiol 144 (1996) 175-182
89. Anstey A.V. Systemic photoprotection with alpha-tocopherol (vitamin E) and beta carotene. Clin Exp Dermatol 27 (2002) 170-176
90. Fazekas Z., Gao D., Saladi R.N., Lu Y., Lebwohl M., and Wei H. Protective effects of lycopene against ultraviolet B-induced photodamage. Nutr Cancer 47 (2003) 181-187
91. Keller K.L., and Fenske N.A. Uses of vitamins A, C, and E and related compounds in dermatology: a review. J Am Acad Dermatol 39 (1998) 611-625
92. Wertz K., Hunziker P.B., Seifert N., Riss G., Neeb M., Steiner G., et al. Beta-carotene interferes with ultraviolet light A-induced gene expression by multiple pathways. J Invest Dermatol 124 (2005) 428-434
93. Klein E.A. Chemoprevention of prostate cancer. Crit Rev Oncol Hematol 54 (2005) 1-10
94. McVean M., and Liebler D.C. Inhibition of UVB induced DNA photodamage in mouse epidermis by topically applied alpha-tocopherol. Carcinogenesis 18 (1997) 1617-1622
95. Gensler H.L., Aickin M., Peng Y.M., and Xu M. Importance of the form of topical vitamin E for prevention of photocarcinogenesis. Nutr Cancer 26 (1996) 183-191
96. McVean M., and Liebler D.C. Prevention of DNA photodamage by vitamin E compounds and sunscreens: roles of ultraviolet absorbance and cellular uptake. Mol Carcinog 24 (1999) 169-176
97. Malafa M.P., Fokum F.D., Mowlavi A., Abusief M., and King M. Vitamin E inhibits melanoma growth in mice. Surgery 131 (2002) 85-91
98. Kogure K., Manabe S., Hama S., Tokumura A., and Fukuzawa K. Potentiation of anti-cancer effect by intravenous administration of vesiculated alpha-tocopheryl hemisuccinate on mouse melanoma in vivo. Cancer Lett 192 (2003) 19-24
99. Kirkpatrick C.S., White E., and Lee J.A. Case-control study of malignant melanoma in Washington State, II: diet, alcohol, and obesity. Am J Epidemiol 139 (1994) 869-880
100. Stryker W.S., Stampfer M.J., Stein E.A., Kaplan L., Louis T.A., Sober A., et al. Diet, plasma levels of beta-carotene and alpha-tocopherol, and risk of malignant melanoma. Am J Epidemiol 131 (1990) 597-611
101. Lonn E., Bosch J., Yusuf S., Sheridan P., Pogue J., Arnold J.M., et al. Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. JAMA 293 (2005) 1338-1347
102. Miller E., Paster-Barrluso R., Dalal D., Rienersina R., Appel L., and Guallar E. Meta-analysis: high-dosage vitamin E may increase all-cause mortality. Ann Intern Med 142 (2005) 167-179
103. Blumberg J., and Block G. The alpha-tocopherol, beta-carotene cancer prevention study in Finland. Nutr Rev 52 (1994) 242-245
104. Blot W.J., Li J.Y., Taylor P.R., Guo W., Dawsey S., Wang G.O., et al. Nutrition intervention trials in Linxian, China: supplementation with specific vitamin/mineral combinations, cancer incidence, and disease-specific mortality in the general population. J Natl Cancer Inst 85 (1993) 1483-1492
105. Bosetti C., Talamini R., Montella M., Negri E., Conti E., Franceschi S., et al. Retinol, carotenoids and the risk of prostate cancer: a case-control study from Italy. Int J Cancer 112 (2004) 689-692
106. Green A., Williams G., Neale R., Hart V., Leslie D., Parsons P., et al. Daily sunscreen application and betacarotene supplementation in prevention of basal-cell and squamous-cell carcinomas of the skin: a randomized controlled trial. Lancet 354 (1999) 723-729
107. Greenberg E.R., Baron J.A., Stukel T.A., Stevens M.M., Mandel J.S., Spencer S.K., et al. A clinical trial of beta carotene to prevent basal-cell and squamous-cell cancers of the skin: the skin cancer prevention study group. N Engl J Med 323 (1990) 789-795
108. Ito Y., Kurata M., Hioki R., Suzuki K., Ochiai J., and Aoki K. Cancer mortality and serum levels of carotenoids, retinol, and tocopherol: a population-based follow-up study of inhabitants of a rural area of Japan. Asian Pac J Cancer Prev 6 (2005) 10-15
109. Nkondjock A., Ghadirian P., Johnson K.C., and Krewski D. Canadian Cancer Registries Epidemiology Research Group. Dietary intake of lycopene is associated with reduced pancreatic cancer risk. J Nutr 135 (2005) 592-597
110. Tamimi R.M., Hankinson S.E., Campos H., Spiegelman D., Zhang S., Colditz G.A., et al. Plasma carotenoids, retinol, and tocopherols and risk of breast cancer. Am J Epidemiol 161 (2005) 153-160
111. Tappel A. Lysosomal and prostasomal hydrolytic enzymes and redox processes and initiation of prostate cancer. Med Hypotheses 64 (2005) 1170-1172
112. Hwang E.S., and Bowen P.E. Can the consumption of tomatoes or lycopene reduce cancer risk?. Integr Cancer Ther 1 (2002) 121-132
113. Aust O., Stahl W., Sies H., Tronnier H., and Heinrich U. Supplementation with tomato-based products increases lycopene, phytofluene, and phytoene levels in human serum and protects against UV-light-induced erythema. Int J Vitam Nutr Res 75 (2005) 54-60
114. Breslow R.A., Alberg A.J., Helzlsouer K.J., Bush T.L., Norkus E.P., Morris J.S., et al. Serological precursors of cancer: malignant melanoma, basal and squamous cell skin cancer, and prediagnostic levels of retinol, beta-carotene, lycopene, alpha-tocopherol, and selenium. Cancer Epidemiol Biomarkers Prev 4 (1995) 837-842
115. Comstock G.W., Helzlsouer K.J., and Bush T.L. Prediagnostic serum levels of carotenoids and vitamin E as related to subsequent cancer in Washington County, Maryland. Am J Clin Nutr 53 Suppl (1991) 260S-264S
116. Millen A.E., Tucker M.A., Hartge P., Halpern A., Elder D.E., Guerry IV D., et al. Diet and melanoma in a case-control study. Cancer Epidemiol Biomarkers Prev 13 (2004) 1042-1051
117. Messina M.J., Persky V., Setchell K.D., and Barnes S. Soy intake and cancer risk: a review of the in vitro and in vivo data. Nutr Cancer 21 (1994) 113-131
118. Rauth S., Kichina J., and Green A. Inhibition of growth and induction of differentiation of metastatic melanoma cells in vitro by genistein: chemosensitivity is regulated by cellular p53. Br J Cancer 75 (1997) 1559-1566
119. Russo A., Cardile V., Lombardo L., Vanella L., and Acquaviva R. Genistin inhibits UV light-induced plasmid DNA damage and cell growth in human melanoma cells. J Nutr Biochem 17 (2006) 103-108
120. Wei H., Saladi R., Lu Y., Wang Y., Palep S.R., Moore J., et al. Isoflavone genistein: photoprotection and clinical implications in dermatology. J Nutr 133 Suppl (2003) 3811S-3819S
121. Lahiri-Chatterjee M., Katiyar S.K., Mohan R.R., and Agarwal R. A flavonoid antioxidant, silymarin, affords exceptionally high protection against tumor promotion in the SENCAR mouse skin tumorigenesis model. Cancer Res 59 (1999) 622-632
122. Singh R.P., and Agarwal R. Flavonoid antioxidant silymarin and skin cancer. Antioxid Redox Signal 4 (2002) 655-663
123. Zhao J., Sharma Y., and Agarwal R. Significant inhibition by the flavonoid antioxidant silymarin against 12-O-tetradecanoylphorbol 13-acetate-caused modulation of antioxidant and inflammatory enzymes, and cyclooxygenase 2 and interleukin 1-alpha expression in SENCAR mouse epidermis: implications in the prevention of stage I tumor promotion. Mol Carcinog 26 (1999) 321-333
124. Singh R.P., and Agarwal R. Mechanisms and preclinical efficacy of silibinin in preventing skin cancer. Eur J Cancer 41 (2005) 1969-1979
125. Ariga T. The antioxidative function, preventive action on disease and utilization of proanthocyanidins. Biofactors 21 (2004) 197-201
126. Cos P., De Bruyne T., Hermans N., Apers S., Berghe D.V., and Vlietinck A.J. Proanthocyanidins in health care: current and new trends. Curr Med Chem 11 (2004) 1345-1359
127. Li W.G., Zhang X.Y., Wu Y.J., and Tian X. Anti-inflammatory effect and mechanism of proanthocyanidins from grape seeds. Acta Pharmacol Sin 22 (2001) 1117-1120
128. Bomser J.A., Singletary K.W., Wallig M.A., and Smith M.A. Inhibition of TPA-induced tumor promotion in CD-1 mouse epidermis by a polyphenolic fraction from grape seeds. Cancer Lett 135 (1999) 151-157
129. Mittal A., Elmets C.A., and Katiyar S.K. Dietary feeding of proanthocyanidins from grape seeds prevents photocarcinogenesis in SKH-1 hairless mice: relationship to decreased fat and lipid peroxidation. Carcinogenesis 24 (2004) 1379-1388
130. Martinez C., Vicente V., Yanez J., Alcaraz M., Castells M.T., Canteras M., et al. The effect of the flavonoid diosmin, grape seed extract and red wine on the pulmonary metastatic B16F10 melanoma. Histol Histopathol 20 (2005) 1121-1129
131. Aggarwal B.B., Bhardwaj A., Aggarwal R.S., Seeram N.P., Shishodia S., and Takada Y. Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res 24 (2004) 2783-2840
132. Niles R.M., McFarland M., Weimer M.B., Redkar A., Fu Y.M., and Meadows G.G. Resveratrol is a potent inducer of apoptosis in human melanoma cells. Cancer Lett 190 (2003) 157-163
133. Aziz M.H., Reagan-Shaw S., Wu J., Longley B.J., and Ahmad N. Chemoprevention of skin cancer by grape constituent resveratrol: relevance to human disease?. FASEB J 19 (2005) 1193-1195
134. Rotruck J.T., Pope A.L., Ganther H.E., Swanson A.B., Hafeman D.G., and Hoekstra W.G. Selenium: biochemical role as a component of glutathione peroxidase. Science 179 (1973) 588-590
135. Whanger P.D. Selenium and its relationship to cancer: an update dagger. Br J Nutr 91 (2004) 11-28
136. Singh R., and El-Bayoumy K. Apoptosis is a critical cellular event in cancer chemoprevention and chemotherapy by selenium compounds. Curr Cancer Drug Targets 4 (2004) 13-28
137. Helzlsouer K.J., Huang H.Y., Alberg A.J., Hoffman S., Burke A., Norkus E.P., et al. Association between alpha-tocopherol, gamma-tocopherol, selenium, and subsequent prostate cancer. J Natl Cancer Inst 92 (2000) 2018-2023
138. Etminan M., FitzGerald J.M., Gleave M., and Chambers K. Intake of selenium in the prevention of prostate cancer: a systematic review and meta-analysis. Cancer Causes Control 16 (2005) 1125-1131
139. Duffield-Lillico A.J., Slate E.H., Reid M.E., Turnbull B.W., Wilkins P.A., Combs Jr. G.F., et al. Nutritional prevention of cancer study group: selenium supplementation and secondary prevention of nonmelanoma skin cancer in a randomized trial. J Natl Cancer Inst 95 (2003) 1477-1481
140. Clark L.C., Combs Jr. G.F., Turnbull B.W., Slate E.H., Chalker D.K., Chow J., et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin: a randomized controlled trial; nutritional prevention of cancer study group. JAMA 276 (1996) 1957-1963
141. Li D., Graef G.L., Yee J.A., and Yan L. Dietary supplementation with high-selenium soy protein reduces pulmonary metastasis of melanoma cells in mice. J Nutr 134 (2004) 1536-1540
142. Vinceti M., Rothman K.J., Bergomi M., Borciani N., Serra L., and Vivoli G. Excess melanoma incidence in a cohort exposed to high levels of environmental selenium. Cancer Epidemiol Biomarkers Prev 7 (1998) 853-856
143. Vinceti M., Bassissi S., Malagoli C., Pellacani G., Alber D., Bergomi M., et al. Environmental exposure to trace elements and risk of cutaneous melanoma. J Expo Anal Environ Epidemiol 15 (2005) 458-462
144. Egan K.M., Sosman J.A., and Blot W.J. Sunlight and reduced risk of cancer: is the real story vitamin D?. J Natl Cancer Inst 97 (2005) 161-163
145. Jacobs E.T., Giuliano A.R., Martinez M.E., Hollis B.W., Reid M.E., and Marshall J.R. Plasma levels of 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D and the risk of prostate cancer. J Steroid Biochem Mol Biol 89-90 (2004) 533-537
146. Kallay E., Bises G., Bajna E., Bieglmayer C., Gerdenitsch W., Steffan I., et al. Colon-specific regulation of vitamin D hydroxylases-a possible approach for tumor prevention. Carcinogenesis 26 (2005) 1581-1589
147. Nakagawa K., Kawaura A., Kato S., Takeda E., and Okano T. 1 alpha, 25-Dihydroxyvitamin D(3) is a preventive factor in the metastasis of lung cancer. Carcinogenesis 26 (2005) 429-440
148. Smedby K.E., Hjalgrim H., Melbye M., Torrång A., Rostgaard K., Munksgaard L., et al. Ultraviolet radiation exposure and risk of malignant lymphomas. J Natl Cancer Inst 97 (2005) 199-209
149. Berwick M., Armstrong B.K., Ben-Porat L., Fine J., Kricker A., Eberle C., et al. Sun exposure and mortality from melanoma. J Natl Cancer Inst 97 (2005) 195-199
150. Bernardi R., Jonson C.S., Modzelewski R.A., and Trump D.L. Antiproliferative effects of 1-alpha, 25-dihydroxyvitamin D(3) and vitamin D analogs on tumor-derived endothelial cells. Endocrinology 143 (2002) 2508-2514
151. Vandewalle B., Wattez N., and Lefebvre J. Effects of vitamin D3 derivatives on growth, differentiation and apoptosis in tumoral colonic HT 29 cells: possible implication of intracellular calcium. Cancer Lett 97 (1995) 99-106
152. Garland C.F. More on preventing skin cancer: sun avoidance will increase incidence of cancers overall. BMJ 327 (2003) 1228
153. Holick M.F. Vitamin D: importance in the prevention of cancers, type 1 diabetes, heart disease, and osteoporosis. Am J Clin Nutr 79 (2004) 362-371
154. Wolpowitz D., and Gilchrest B.A. The vitamin D questions: how much do you need and how should you get it?. J Am Acad Dermatol 54 (2006) 301-317
155. Gross M.D. Vitamin D and calcium in the prevention of prostate and colon cancer: new approaches for the identification of needs. J Nutr 135 (2005) 326-331
156. Hartman T.J., Albert P.S., Snyder K., Slattery M.L., Caan B., Paskett E., et al. The association of calcium and vitamin D with risk of colorectal adenomas. J Nutr 135 (2005) 252-259
157. Weinstock M.A., Stampfer M.J., Lew R.A., Willett W.C., and Sober A.J. Case-control study of melanoma and dietary vitamin D: implications for advocacy of sun protection and sunscreen use. J Invest Dermatol 98 (1992) 809-811
158. Xiaoguang C., Hongyan L., Xiaohong L., Zhaodi F., Yan L., Lihua T., et al. Cancer chemopreventive and therapeutic activities of red ginseng. J Ethnopharmacol 60 (1998) 71-78
159. Mochizuki M., Yoo Y.C., Matsuzawa K., Sato K., Saiki I., Tono-oka S., et al. Inhibitory effect of tumor metastasis in mice by saponins, ginsenoside Rb2, 20(R)- and 20(S)-ginsenoside-Rg3, of red ginseng. Biol Pharm Bull 18 (1995) 1197-1202
160. Yun T.K. Experimental and epidemiological evidence on non-organ specific cancer preventive effect of Korean ginseng and identification of active compounds. Mutat Res 523-524 (2003) 63-74
161. Lluria-Prevatt M., Morreale J., Gregus J., Alberts D.S., Kaper F., Giaccia A., et al. Effects of perillyl alcohol on melanoma in the TPras mouse model. Cancer Epidemiol Biomarkers Prev 11 (2002) 573-579
162. Bystryn J.C., and Reynolds S.R. Melanoma vaccines: what we know so far. Oncology 19 (2005) 97-108
163. Pfahlberg A., Botev I.N., Kolmel K.F., and Gefeller O. Vaccination and melanoma risk. Int J Cancer 102 (2002) 96-97
164. Krone B., Kolmel K.F., Henz B.M., and Grange J.M. Protection against melanoma by vaccination with bacille Calmette-Guerin (BCG) and/or vaccinia: an epidemiology-based hypothesis on the nature of a melanoma risk factor and its immunological control. Eur J Cancer 41 (2005) 104-117
165. Schon M., Bong A.B., Drewniok C., Herz J., Geilen C.C., Reifenberger J., et al. Tumor-selective induction of apoptosis and the small-molecule immune response modifier imiquimod. J Natl Cancer Inst 95 (2003) 1138-1149
166. Tran H., Moreno G., and Shumack S. Imiquimod as a dermatological therapy. Expert Opin Pharmacother 5 (2004) 427-438
167. Burns C.A., and Brown M.D. Imiquimod for the treatment of skin cancer. Dermatol Clin 23 (2005) 151-164
168. Munoz C.M., Sanchez J.L., and Martin-Garcia R.F. Successful treatment of persistent melanoma in situ with 5% imiquimod cream. Dermatol Surg 30 (2004) 1543-1545
169. Wolf I.H., Cerroni L., Kodama K., and Kerl H. Treatment of lentigo maligna (melanoma in situ) with the immune response modifier imiquimod. Arch Dermatol 141 (2005) 510-514
170. Willman C.L. Targeted AML therapy: new biologic paradigms and therapeutic opportunities. Leukemia 15 (2001) 690-694
171. Niles R.M. Vitamin A and cancer. Nutrition 16 (2000) 573-576
172. Kovach B.T., Sams H.H., and Stasko T. Systemic strategies for chemoprevention of skin cancers in transplant recipients. Clin Transplant 19 (2005) 726-734
173. Zhang H., and Rosdahl I. Expression profiles of p53, p21, bax and bcl-2 proteins in all-trans-retinoic acid treated primary and metastatic melanoma cells. Int J Oncol 25 (2004) 303-308
174. Zhang H., and Rosdahl I. Expression profiles of Id1 and p16 proteins in all-trans-retinoic acid-induced apoptosis and cell cycle re-distribution in melanoma. Cancer Lett 217 (2005) 33-41
175. Weinzweig J., Tattini C., Lynch S., Zienowicz R., Weinzweig N., Spangenberger A., et al. Investigation of the growth and metastasis of malignant melanoma in a murine model: the role of supplemental vitamin A. Plast Reconstr Surg 112 (2003) 152-158
176. Edwards L., and Jaffe P. The effect of topical tretinoin on dysplastic nevi: a preliminary trial. Arch Dermatol 126 (1990) 494-499
177. Halpern A.C., Schuchter L.M., Elder D.E., Guerry IV D., Elenitsas R., Trock B., et al. Effects of topical tretinoin on dysplastic nevi. J Clin Oncol 12 (1994) 1028-1035
178. Meyskens Jr. F.L., Edwards L., and Levine N.S. Role of topical tretinoin in melanoma and dysplastic nevi. J Am Acad Dermatol 15 (1986) 822-825
179. Stam-Posthuma J.J., Vink J., le Cessie S., Bruijn J.A., Bergman W., and Pavel S. Effect of topical tretinoin under occlusion on atypical nevi. Melanoma Res 8 (1998) 539-548
180. Edwards L., Meyskens F., and Levine N. Effect of oral isotretinoin on dysplastic nevi. J Am Acad Dermatol 20 (1989) 257-260
181. Triozzi P.L., Walker M.J., Pellegrini A.E., and Dayton M.A. Isotretinoin and recombinant interferon alfa-2a therapy of metastatic malignant melanoma. Cancer Invest 14 (1996) 293-298
182. Rosenthal M.A., and Oratz R. Phase II clinical trial of recombinant alpha 2b interferon and 13 cis retinoic acid in patients with metastatic melanoma. Am J Clin Oncol 21 (1998) 352-354
183. Wallace H.M., and Fraser A.V. Polyamine analogues as anticancer drugs. Biochem Soc Trans 31 (2003) 393-396
184. Sanborn G., Niederkorn J., Kan-Mitchell J., and Alberts D. Prevention of metastasis of intraocular melanoma in mice treated with difluoromethylornithine. Graefes Arch Clin Exp Ophthalmol 230 (1992) 72-77
185. Meyskens Jr. F.L., and Gerner E.W. Development of difluoromethylornithine (DFMO) as a chemoprevention agent. Clin Cancer Res 5 (1999) 945-951
186. Love R.R., Carbone P.P., Verma A.K., Gilmore D., Carey P., Tutsch K.D., et al. Randomized phase I chemoprevention dose-seeking study of alpha-difluoromethylornithine. J Natl Cancer Inst 85 (1993) 732-737
187. Love R.R., Jacoby R., Newton M.A., Tutsch K.D., Simon K., Pomplun M., et al. A randomized, placebo-controlled trial of low-dose alpha-difluoromethylornithine in individuals at risk for colorectal cancer. Cancer Epidemiol Biomarkers Prev 7 (1998) 989-992
188. Yarosh D., Klein J., O'Connor A., Hawk J., Rafal E., and Wolf P. Effect of topically applied T4 endonuclease V in liposomes on skin cancer in xeroderma pigmentosum: a randomized study, xeroderma pigmentosum study group. Lancet 357 (2001) 926-929
189. Yarosh D.B. DNA repair, immunosuppression, and skin cancer. Cutis 74 Suppl (2004) 10-13